Recent groundbreaking research conducted at Boston University’s Chobanian & Avedisian School of Medicine has unveiled a pivotal cellular mechanism that may govern the transition from these early premalignant states to invasive lung cancer. The study identifies a specific microRNA molecule—miR-149-5p—that is significantly upregulated in lesions exhibiting progressive severity. MicroRNAs are short, non-coding RNA strands that modulate gene expression, typically by silencing target messenger RNAs, thereby controlling protein synthesis and cellular behavior.

Through meticulous RNA sequencing and microRNA profiling of bronchial biopsies collected from patients at Roswell Park Comprehensive Cancer Center, the researchers explored gene expression patterns linked with lesion advancement. Among the 167 biopsies analyzed from 30 subjects, miR-149-5p emerged as the dominant microRNA whose overexpression corresponded inversely with the levels of NLRC5, a master regulator responsible for activating immune system genes pivotal for identifying and eliminating abnormal cells.

This inverse relationship implies that high miR-149-5p expression undermines the body’s immune surveillance by repressing NLRC5-mediated pathways. Consequently, transformed airway epithelial cells can evade immune detection, creating an immunosuppressive microenvironment that favors lesion persistence and malignant progression. This immune evasion strategy is corroborated by spatial analyses of biopsy tissues showing a conspicuous scarcity of immune cells proximal to the bronchial cells laden with elevated miR-149-5p and diminished NLRC5.

Notably, lesions demonstrating the greatest degree of severity and propensity to progress were associated with the highest expression of miR-149-5p, underscoring its potential as a biomarker for aggressive disease. These findings illuminate a previously unappreciated axis of immune escape at the premalignant stage, pointing toward the critical role of epithelial microRNA regulation in modulating host-tumor interactions before invasive cancer develops.

Jennifer Beane, PhD, an associate professor of medicine and the study’s corresponding author, emphasized the clinical implications of these insights. She articulated that understanding the molecular events dictating whether lesions regress, remain stable, or deteriorate provides a strategic foothold to intercept lung cancer at its inception. By distinguishing lesions poised for malignant transformation, clinicians could conceivably deploy targeted interventions to halt or reverse disease progression, significantly reducing lung cancer mortality rates.

The investigative team employed cutting-edge spatial transcriptomics to localize both the expression of miR-149-5p and its downstream targets within the intricate tissue microenvironment. This approach enabled quantification of the spatial relationships between transformed epithelial cells and infiltrating immune populations within the same tissue context, revealing the localized impact of miR-149-5p on immune cell exclusion.

Furthermore, the research sheds new light on how chronic inhalational exposure to environmental pollutants perpetuates a cycle of inflammation, cellular injury, and immune disruption. Insights gleaned from this study could pave the way for novel therapeutic avenues that restore immune surveillance capabilities, either by directly antagonizing miR-149-5p or by enhancing NLRC5 expression, thus reactivating the immune system’s natural tumor defense mechanisms at a premalignant stage.

This work also spotlights the need to broaden our understanding of lung carcinogenesis beyond genetic mutations within cancer cells, encompassing the crucial role of non-coding RNAs and the immune landscape of the bronchial epithelium. As inhaled toxicants and environmental challenges continue to rise globally, unraveling these complex molecular crosstalk pathways becomes ever more pressing for public health and cancer prevention strategies.

Importantly, these discoveries highlight a possible molecular target for interception—a therapeutic window during which lung cancer may be prevented rather than treated post-invasion. The prospect of intercepting disease progression at the cellular and molecular level promises to redefine the future of lung cancer care, shifting the paradigm from late-stage interventions to early, precision-based preventive strategies.

The study’s findings appear in the prestigious journal Cancer Immunology Research, underscoring a collaborative, multidisciplinary effort that integrates molecular biology, immunology, computational analysis, and clinical pathology. The research received funding from the National Institutes of Health alongside sponsored support from Johnson and Johnson and prominent cancer research foundations, reflecting the high-impact and translational potential of this work.

As research continues to unravel the subtle mechanisms by which premalignant cellular populations evade immune detection, the scientific community moves closer to harnessing these insights for early diagnostics and immunomodulatory therapies. This could herald a new era in lung cancer prevention, with the promise of intercepting the disease in its most nascent and curable stages, substantially improving patient outcomes worldwide.

Subject of Research: Cells
Article Title: Up-regulation of an epithelial miRNA is associated with immune evasion in progressive bronchial premalignant lesions
News Publication Date: 11-Feb-2026
Web References: 10.1158/2326-6066.
Keywords: Health and medicine

Fatty acid metabolism has long been implicated in cancer biology, with enzymes involved in lipid synthesis often hijacked to fuel aggressive tumor growth. However, the enzyme 3-hydroxyacyl-CoA dehydratase 3 (HACD3), a member of the very long-chain fatty acid dehydratase family, exhibits relatively mild enzymatic dehydratase activity, prompting scientists to explore whether its role in cancer extends beyond canonical metabolic pathways. The new research reveals that HACD3 is more than just a metabolic player; it acts as a sophisticated molecular regulator that promotes tumor malignancy by modulating critical signaling pathways.

Investigations demonstrated that HACD3 is significantly overexpressed at both the mRNA and protein levels in NSCLC tissues and cell lines. This heightened expression correlates with aggressive phenotypes, including increased cellular proliferation and enhanced migratory capacity in vitro, as well as accelerated tumor growth when NSCLC cells are implanted in immunocompromised mice. These functional assays provide compelling evidence that HACD3 is not a mere bystander but an active facilitator of lung cancer progression.

Intriguingly, the researchers went beyond correlation by deploying a genetic knockout strategy. By engineering mice completely deficient in Hacd3, they created a robust model to investigate the enzyme’s role in vivo. These knockout animals, when subjected to the carcinogen urethane known to induce lung tumors, showed a striking reduction in tumor burden compared to wild-type controls. Fascinatingly, this tumor suppression effect occurred without significant changes in overall fatty acid composition, indicating that HACD3’s pro-tumorigenic influence operates independently of its classic enzymatic function in fatty acid metabolism.

Delving deeper into the molecular mechanisms, the study employed transcriptomic analyses paired with co-immunoprecipitation to identify proteins that physically interact with HACD3. They discovered direct binding between HACD3 and components of the mitogen-activated protein kinase (MAPK) pathway, specifically the kinases MKK7 and MAPK10 (also known as JNK3). This interaction appears to effectively suppress MAPK signaling, a pathway traditionally known for its tumor-suppressive effects via regulation of cellular stress responses and apoptosis.

HACD3’s binding to MKK7 and MAPK10 hinders their ability to propagate anti-tumorigenic signals, thus tipping the balance in favor of malignant cell survival and proliferation. Strikingly, the core pro-oncogenic activity of HACD3 was mapped to a discrete C-terminal domain spanning amino acid residues 231 to 259. This region mediates the protein-protein interactions necessary for suppressing MAPK pathway activity, uncoupling HACD3’s oncogenic role from its enzymatic domain.

The implications of these insights extend well beyond basic biology. Targeting the HACD3-MKK7-MAPK10 axis with therapeutic agents—such as small molecule inhibitors or peptides designed to disrupt these protein interactions—could unleash the suppressed MAPK signaling cascade, potentially restoring cancer cell sensitivity to apoptosis and halting tumor progression. This mechanism represents a sharp departure from classical approaches aimed solely at interfering with metabolic enzymes’ catalytic functions.

Moreover, the study highlights the versatility of metabolic enzymes, which can moonlight as crucial regulators in complex signaling networks governing tumor biology. HACD3 is emblematic of such multifunctionality, challenging the field to consider how other metabolic enzymes might similarly influence cancer by non-catalytic means. This paradigm shift could uncover an array of previously unappreciated molecular vulnerabilities in cancer cells.

NSCLC remains a formidable clinical challenge due to its heterogeneity and frequent resistance to existing therapies. The identification of HACD3 as a pro-tumorigenic factor offers a novel target that might circumvent some resistance mechanisms associated with the MAPK signaling pathway. Since HACD3’s role is independent of its enzymatic function, drugs designed to disrupt its protein-protein interactions may avoid compensatory metabolic adaptations, potentially improving therapeutic efficacy.

The research was comprehensive, leveraging bioinformatics databases such as GEPIA and the Human Protein Atlas to analyze HACD3 expression patterns, and deploying cutting-edge molecular biology techniques, including the generation of truncated plasmids and synthetic peptides, to functionally dissect the domains responsible for tumorigenic interactions. Additionally, cutting-edge lipidomic profiling via gas chromatography–mass spectrometry confirmed the mechanistic independence from fatty acid metabolic alterations.

As the study demonstrates, cancer progression is often driven by a complex interplay between metabolism and intracellular signaling. The discovery that HACD3 acts primarily through suppression of a tumor-inhibitory MAPK signaling axis—not through modification of lipid metabolism—provides a fresh lens through which to interpret tumor biology and drug resistance.

The field now faces a tantalizing challenge: to develop and test agents that can selectively disrupt HACD3’s pro-oncogenic domain or block its interaction with MKK7 and MAPK10. Such therapeutic strategies might be particularly valuable for patients with NSCLC exhibiting high HACD3 expression, providing a biomarker-driven approach to personalized cancer treatment.

In conclusion, this landmark study elucidates a previously unrecognized tumor-promoting role for HACD3 in lung cancer. By suppressing the MKK7/MAPK10 signaling axis, HACD3 enables cancer cells to bypass critical growth restraints, promoting malignant progression. These findings not only deepen our grasp of NSCLC pathobiology but also unveil new avenues for innovative therapeutic interventions aimed at improving patient outcomes in a cancer type that continues to exact a heavy toll globally.

Subject of Research: Non-Small Cell Lung Cancer (NSCLC) and the molecular role of HACD3 in tumor progression

Article Title: HACD3 promotes malignant progression of NSCLC by suppressing the MKK7/MAPK10 signaling axis

Article References:
Wang, X., Liang, H., Du, Q. et al. HACD3 promotes malignant progression of NSCLC by suppressing the MKK7/MAPK10 signaling axis. BMC Cancer 25, 1317 (2025). https://doi.org/10.1186/s12885-025-14621-y

Image Credits: Scienmag.com

DOI: https://doi.org/10.1186/s12885-025-14621-y